Aquestive Therapeutics News - November 2026
🟢 Aquestive Therapeutics is trading 17.89% up in pre-market — no clear catalyst identified
Aquestive Therapeutics is trading 17.89% higher at $4.48 in pre-market, with no new company-specific announcement found explaining the November 5 move. - The...
Aquestive Therapeutics missed third quarter 2026 revenue and EPS estimates while securing an Anaphylm PDUFA date
Aquestive Therapeutics reported a significant revenue decline in the third quarter of 2026, largely attributed to the timing of manufacturing orders for...
Aquestive Therapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Aquestive Therapeutics is expected to report Q3 2026 revenue of $15.42 million and a consensus EPS loss of $0.10, with the stock trading at $5.24 against a...